Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
AstraZeneca
Incyte Corporation
Shanghai YingLi Pharmaceutical Co. Ltd.
University of Texas Southwestern Medical Center
Chinese PLA General Hospital